Abstract
Present treatment options for hepatocellular cancer (HCC) are limited to those individuals with good liver function and early stage disease. Unfortunately this includes only a minority of patients, few of which are actually cured of their cancer. Over the last 15-20 years biotechnology has made a very significant impact on medical research, to the extent that we know very much more about the regulation of normal cell growth and death, as well as the mechanisms underlying its disruption in disease processes. This knowledge has and is being rapidly exploited by academic and pharmaceutical organisations, often in collaboration. The result is the development, testing and steady introduction of therapies that target specific abnormalities in cancer cells. Although the safety and effectiveness of the majority of these agents has yet to be established in cirrhotic patients with HCC, we are hopeful that we will shortly see an increase in effective treatment options available for clinical use this disease. This review focuses on aberrant cancer proteins and pathways relevant to HCC, as well as the novel therapies or strategies targeting them, that are currently in the development or testing stages.
Keywords: Hepatocellular Cancer, new therapies, molecular targets, small molecule inhibitors, receptor tyrosine kinase
Current Pharmaceutical Design
Title: The Development of Targeted Therapies for Hepatocellular Cancer
Volume: 13 Issue: 32
Author(s): D. Chattopadhyay, D. M. Manas and H. L. Reeves
Affiliation:
Keywords: Hepatocellular Cancer, new therapies, molecular targets, small molecule inhibitors, receptor tyrosine kinase
Abstract: Present treatment options for hepatocellular cancer (HCC) are limited to those individuals with good liver function and early stage disease. Unfortunately this includes only a minority of patients, few of which are actually cured of their cancer. Over the last 15-20 years biotechnology has made a very significant impact on medical research, to the extent that we know very much more about the regulation of normal cell growth and death, as well as the mechanisms underlying its disruption in disease processes. This knowledge has and is being rapidly exploited by academic and pharmaceutical organisations, often in collaboration. The result is the development, testing and steady introduction of therapies that target specific abnormalities in cancer cells. Although the safety and effectiveness of the majority of these agents has yet to be established in cirrhotic patients with HCC, we are hopeful that we will shortly see an increase in effective treatment options available for clinical use this disease. This review focuses on aberrant cancer proteins and pathways relevant to HCC, as well as the novel therapies or strategies targeting them, that are currently in the development or testing stages.
Export Options
About this article
Cite this article as:
Chattopadhyay D., Manas M. D. and Reeves L. H., The Development of Targeted Therapies for Hepatocellular Cancer, Current Pharmaceutical Design 2007; 13 (32) . https://dx.doi.org/10.2174/138161207782360717
DOI https://dx.doi.org/10.2174/138161207782360717 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Molecular Imaging of Neuropsychiatry and Boron Neutron Capture Therapy in Neuro-oncology
Current Molecular Imaging (Discontinued) MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy
Current Medicinal Chemistry Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Immunomodulation in Polytrauma and Polymicrobial Sepsis - Where Do We Stand?
Recent Patents on Inflammation & Allergy Drug Discovery Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation via P53 Activation in Human Renal Carcinoma ACHN Cells
Protein & Peptide Letters Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Environmental Chemicals and Breast Cancer Risk – A Structural Chemistry Perspective
Current Medicinal Chemistry Cancer and Treatment Modalities
Current Cancer Therapy Reviews Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
Current Cancer Drug Targets Coffea arabica Bean Extracts and Vitamin C: A Novel Combination Unleashes MCF-7 Cell Death
Current Pharmaceutical Biotechnology Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Non-Alcoholic Fatty Liver Disease in Children
Current Nutrition & Food Science Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases
Protein & Peptide Letters